Key points are not available for this paper at this time.
Orlistat shows no DKA association in this cross-sectional analysis; leaves open rare-event detection in prospective diabetic cohorts.
rlistat is a drug frequently prescribed as an adjuvant in weight control therapy (1-2). Orlistat inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract to decrease the systemic absorption of dietary fat (1,2). In clinical trials, steatorrhoea and other gastrointestinal disorders are the most frequently reported side effects (3). Other reported adverse effects include hypertension (4) and depression (5). No cases of severe hyperglycemia or diabetic ketoacidosis (DKA) have been previously reported with this drug.
No takes yet. Share an insight, caveat, or question.
Guerrero-Igea et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: